# Alicia Secor

> Alicia Secor is a Boston-based biotechnology executive with more than 30 years of experience building life-sciences businesses, guiding product development and commercialization, raising capital, and navigating strategic transactions. She became President and CEO of Paratus Sciences in 2026 after leading Atalanta Therapeutics from formation to the threshold of clinical development, previously serving as CEO of Juniper Pharmaceuticals through its acquisition by Catalent and holding senior operating roles at Zafgen, Synageva BioPharma, and Genzyme. She also serves on the board of Zevra Therapeutics and mentors emerging life-sciences leaders through the Termeer Institute.

- **Role:** President & Chief Executive Officer at Paratus Sciences
- **Organizations:** Paratus Sciences, Zevra Therapeutics, Atalanta Therapeutics, Juniper Pharmaceuticals, Zafgen, Synageva BioPharma, Genzyme, Alkermes, Centocor, Pfizer, Orchard Therapeutics, G1 Therapeutics, GW Pharmaceuticals, Foundation for Prader-Willi Research, Termeer Institute
- **Education:** B.S. in Health Administration, University of New Hampshire, MBA, Northeastern University, D’Amore-McKim School of Business
- **Known for:** Led Juniper Pharmaceuticals through a turnaround and its 2018 acquisition by Catalent., Led Atalanta Therapeutics from formation to the cusp of clinical-stage development., Launched Atalanta publicly in 2021 with $110 million in committed funding and strategic collaborations with Biogen and Genentech.

## Career timeline

- **Early career** — Began at Pfizer as a hospital-based sales representative, then worked in clinical and commercial operations at Centocor and in business development at Alkermes.
- **1998-2013** — Spent 15 years at Genzyme in roles of increasing responsibility, culminating as vice president and general manager of Metabolic Diseases.
- **2013** — Served as senior vice president and chief operating officer at Synageva BioPharma.
- **2014-2016** — Served as chief commercial officer at Zafgen.
- **2016-2018** — Led Juniper Pharmaceuticals as president and CEO until its acquisition by Catalent in August 2018.
- **2018-2024** — Served on Orchard Therapeutics' board until the company was acquired by Kyowa Kirin.
- **2019-2025** — Served as president, CEO, and director of Atalanta Therapeutics, leading it from formation to the cusp of clinical development.
- **2021** — Publicly launched Atalanta with $110 million in committed funding and collaborations with Biogen and Genentech.
- **2025** — Closed an oversubscribed $97 million Series B at Atalanta; stepped down in a planned leadership transition in June and joined Zevra Therapeutics' board in December.
- **2026-present** — Serves as president, CEO, and director of Paratus Sciences, while continuing as a director of Zevra Therapeutics.

## Achievements

- Led Juniper Pharmaceuticals through a turnaround and its 2018 acquisition by Catalent.
- Led Atalanta Therapeutics from formation to the cusp of clinical-stage development.
- Launched Atalanta publicly in 2021 with $110 million in committed funding and strategic collaborations with Biogen and Genentech.
- Closed Atalanta's oversubscribed $97 million Series B in 2025, bringing capital generated from financings and partnerships to $262 million.
- Held global business responsibility during a 15-year Genzyme tenure and helped advance products through development, launch, and expansion.
- Served on the boards of Orchard Therapeutics, G1 Therapeutics, and GW Pharmaceuticals before each company was acquired.
- Served five years on the board of the nonprofit Foundation for Prader-Willi Research.
- Mentors first-time life-sciences CEOs through the Termeer Institute.

## Latest updates

- **2026-04** — Paratus publicly announced Secor as President and CEO and a member of its board, alongside additions in finance, clinical development, and medical advising.
- **2025-12** — Joined the board of Zevra Therapeutics and was appointed to its Audit and Compensation Committees.
- **2025-06** — Stepped down as Atalanta Therapeutics CEO in a planned transition after six years, remaining an adviser during the handoff.
- **2025-01** — As Atalanta CEO, announced an oversubscribed $97 million Series B financing to support the company's move toward clinical trials.

## Links

- Website: https://paratussciences.com
- LinkedIn: https://www.linkedin.com/in/alicia-secor-9b444025

---

Profile page: https://yespress.io/alicia-secor
Published by YesPress — https://yespress.io
Last updated: 2026-08-10